ARS Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ARS Pharmaceuticals, Inc. (SPRY) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income8.00-54.37-34.68-20.24-1.07
Depreciation & Amortization-7.18-6.780.030.210.01
Stock Based Compensation14.539.245.842.833.54
Change in Working Capital-1.81-7.36-12.75-0.366.46
Change in Accounts Receivable-8.180.000.000.000.00
Change in Inventory-5.950.000.000.000.00
Change in Accounts Payable16.43-2.78-10.290.971.19
Change in Other Working Capital-4.12-1.45-1.151.18-1.69
Other Operating Activities0.009.250.140.000.12
Net Cash from Operating Activities13.55-59.27-40.08-17.569.07
Investing Activities
Capital Expenditures-0.56-0.18-0.20-0.06-0.92
Purchases of Investments-356.04-272.010.000.000.00
Sales/Maturities of Investments258.00185.000.000.000.00
Other Investing Activities-7.500.000.000.000.00
Net Cash from Investing Activities-106.10-87.18-0.20-0.06-0.92
Financing Activities
Debt Repayment69.380.00-8.68-1.82-0.70
Common Stock Issued3.026.900.570.170.10
Other Financing Activities0.000.00198.840.00-2.61
Net Cash from Financing Activities72.406.90190.7353.165.10
Summary
Net Change in Cash-20.15-139.55150.4635.5414.17
Cash at Beginning of Period70.97210.5260.0624.5210.53
Cash at End of Period50.8270.97210.5260.06386.92
Free Cash Flow12.99-59.44-40.28-17.629.07
Supplemental Disclosures
Interest Paid0.000.000.370.580.33